 This is a prospective, longitudinal cohort study of a 6-week clinical intervention with Chinese herbs in advanced Stage 4 NSCLC patients All the active patients who have histologically or cytologically proven metastatic NSCLC with Eastern Cooperative Oncology Group ECOG performance status of 0 -2 will be eligible to participate in the study. Quality of life will be assessed by FACT-L and Edmonton Symptom Assessment System ESAS questionnaires. Patient will be instructed to complete a diary each day to confirm adherence to treatment and to indicate the reasons that any doses were missed or treatment was stopped. 